AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Xeris Biopharma Inc. (XERS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

3.20

-0.02 (-0.62%)

At close: Jan 17, 2025, 3:59 PM

3.24

1.16%

After-hours Jan 17, 2025, 06:13 PM EST

undefined% (undefined)

Bid	3.19
Market Cap	477.06M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.43
PE Ratio (ttm)	-7.44
Forward PE	n/a
Analyst	Strong Buy

Ask	3.25
Volume	876,311
Avg. Volume (20D)	1,656,337
Open	3.24
Previous Close	3.22
Day's Range	3.15 - 3.25
52-Week Range	1.69 - 3.87
Beta	undefined

About XERS

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhi...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 21, 2018

Employees 377

Stock Exchange NASDAQ

Ticker Symbol XERS

Website https://www.xerispharma.com

Analyst Forecast

According to 3 analyst ratings, the average rating for XERS stock is "Strong Buy." The 12-month stock price forecast is $5, which is an increase of 56.25% from the latest price.

Buy 66.67%

Hold 33.33%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Xeris Biopharma Inc. is scheduled to release its earnings on Mar 5, 2025, before market opens.
Analysts project revenue of $53.27M, reflecting a 20.00% YoY growth and earnings per share of -0.08, making a -20.00% decrease YoY.

Why Price Moved

5 months ago

+4.69%

Xeris Biopharma shares are trading higher after th... Unlock content with Pro Subscription

8 months ago

+0.53%

Xeris shares are trading higher after the company announced an exclusive worldwide collaboration and license agreement with Beta Bionics.

News

1 week ago · businesswire.com

Xeris Expects to Exceed Full-Year 2024 Financial Guidance

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) today announced it expects to generate total 2024 revenue of $203 million, which will exceed previously announce...

1 week ago · businesswire.com

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializ...

1 month ago · businesswire.com

Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercial...

2 months ago · seekingalpha.com

Xeris Biopharma Holdings, Inc. (XERS) Q3 2024 Earnings Call Transcript

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants John Shannon - Chief Executive Officer Steve Pieper - Chief Financial Of...

2 months ago · zacks.com

Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Xeris Biopharma (XERS) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metri...

2 months ago · zacks.com

Xeris Biopharma (XERS) Reports Q3 Loss, Tops Revenue Estimates

Xeris Biopharma (XERS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.09 per share a year ago.

2 months ago · businesswire.com

Xeris Biopharma Reports Third Quarter 2024 Financial Results

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing...

2 months ago · businesswire.com

Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024

2 months ago · seekingalpha.com

Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive

Xeris Biopharma Holdings, Inc. is an overlooked specialty pharmaceutical company with three FDA-approved products, utilizing its proprietary XeriSol and XeriJect technologies to develop innovative inj...